HOUSE BILL No. 2747

By Committee on Health and Human Services

Requested by Representative Oropeza on behalf of Representative Woodard

2-7

AN ACT concerning health professions and practices; relating to pharmacists; expanding the pharmacist scope of practice to include initiation of therapy for HIV post-exposure prophylaxis; amending K.S.A. 2023 Supp. 65-16,131 and repealing the existing section.

Be it enacted by the Legislature of the State of Kansas:

Section 1. K.S.A. 2023 Supp. 65-16,131 is hereby amended to read as follows: 65-16,131. (a) (1) A pharmacist may initiate therapy within the framework of a statewide protocol for the following health conditions:

- $\frac{(1)}{(A)}$ Influenza;
 - (2)(B) streptococcal pharyngitis; or
- (3)(C) urinary tract infection.
- (2) A pharmacist may initiate prophylactic therapy within the framework of a statewide protocol for post-exposure to human immunodeficiency virus.
- (b) The collaborative drug therapy management advisory committee established pursuant to K.S.A. 65-1677, and amendments thereto, may adopt a statewide protocol for each condition listed in subsection (a). In establishing such statewide protocols, the committee shall specify:
- (1) The medications or categories of medications included in the protocol for each health condition;
- (2) the training or qualifications required for pharmacists to implement the protocols;
- (3) requirements for documentation and maintenance of records, including patient inclusion and exclusion criteria, medical referral criteria, patient assessment tools based on current clinical guidelines, follow-up monitoring or care plans and the pharmacist's adherence to the applicable protocols; and
- (4) communication requirements, including, but not limited to, notification to the patient's personal or primary care provider.
- (c) The board may deny an application or renewal or revoke or suspend the license of a pharmacist upon a finding that the pharmacist has violated the provisions of this section or failed to practice within the framework of statewide protocols established pursuant to this section by the collaborative drug therapy management advisory committee.

HB 2747 2

1 (d) This section shall take effect and be in force on and after July 1, 2 2022.

- 3 Sec. 2. K.S.A. 2023 Supp. 65-16,131 is hereby repealed.
- Sec. 3. This act shall take effect and be in force from and after its publication in the statute book.